Vaxcyte Corporate Presentation

Critical Manufacturing Foundation Established for PCV Franchise Designed to Provide Robust & Scalable Capacity to Independently Supply Market 27 27 Strategic Alignment with Best-in-Class CDMO Lonza + Overview / Structure: • • End-to-end "turnkey" supply established at marquee Swiss facility Fee-for-service relationship with risk sharing to align the parties Status: • • · • • • • Manufactured, tested and released GMP critical raw materials (eCRMⓇ & 24 polysaccharides) Manufactured, tested and released the 24 GMP conjugated drug substances (DS) Completed GMP drug product (DP) manufacture (formulation, fill and finish) Anticipated completion of remaining DP testing and release, as well as documentation of stability, is expected prior to IND application filing and supply for VAX-24 Phase 1/2 clinical development Commercial production capacity available at same site using existing infrastructure or Ibex capacity coming on-line Exclusive License to Cell-Free Protein Synthesis Platform SUTRO BIOPHARMA Exclusive, worldwide, royalty-bearing, sub-licensable license for field of vaccines to treat or prevent infectious disease (4% royalty) Sutro Biopharma source of cell-free extract and custom reagents VAX-24 Manufacturing Process / Status Dev Campaign GMP eCRM Campaign Dev Campaign Dev Campaign GMP Conjugate Campaign x 24 GMP Polysaccharide Campaign x 24 Formulation/Fill/Finish VAX-24 Drug Product Testing & Release о

View entire presentation